ClinicalTrials.gg
CompletedNCT02407756Updated Nov 27, 2020Results posted

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

A Phase 2 interventional study of Dupilumab in Atopic Dermatitis, sponsored by Regeneron Pharmaceuticals. Completed at 26 sites in 6 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2020-11-27.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
78
Allocation
Non-randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 50 studies testing dupilumab in Dermatitis, Atopic — 4 open to participants now, 6 under way, none of them phase 3. dupilumab · Dermatitis, Atopic.

Enrollment
25th of 50
78 · median 75
Started
2015
with 3 others
Phase 2
7 of 50
none open now
Registered
12th of 50
by date
Lead sponsor
22 of 50
Regeneron Pharmaceuticals

Among the 50 studies testing dupilumab in Dermatitis, Atopic, this one is the 25th largest by enrollment, is one of 4 that started in 2015, is one of 7 in phase 2, and was the 12th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 50 studies testing dupilumab in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 50 studies testing dupilumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The primary objective of the study is to characterize the safety and pharmacokinetics (PK) of dupilumab in pediatric patients with moderate-to-severe atopic dermatitis (AD) (for adolescents ≥12 to \<18 years of age) or severe AD (for children ≥6 to \<12 years of age).

The secondary objective of the study is to explore the immunogenicity and efficacy of dupilumab in pediatric patients with moderate-to-severe AD (for adolescents ≥12 to \<18 years of age) or severe AD (for children ≥6 to \<12 years of age).

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Male or female patients ≥6 to \<18 years of age with a diagnosis of 1. Atopic Dermatitis whose disease cannot be adequately controlled with topical medications
  2. Minimum disease severity, as defined by Investigator's Global Assessment (IGA)

    1. IGA = 3 or 4 in adolescents ≥12 to \<18 year of age
    2. IGA = 4 in children ≥6 to \<12 years of age

Key Exclusion Criteria:

  1. Recent treatment (within specific time windows before the baseline visit) with systemic agents for eg. Systemic , live (attenuated) vaccines and other drugs including biologics
  2. History of any of the following infections:

    1. Any systemic infection requiring treatment within 4 weeks before the baseline visit
    2. Superficial skin infections within 1 week before the baseline visit
    3. Known history of infection
    4. History of seropositivity to or C screening tests
    5. History of clinical endoparasitosis (ie, helminthic infection) within 12 months before the baseline visit, or high risk of helminthic infection, unless subsequent medical assessments (e.g. stool exam, blood tests, etc.) have ruled out the possibility of parasite infection/infestation
  3. History of within 5 years before the baseline visit
  4. Persistent (confirmed by repeated tests ≥2 weeks apart) elevated transaminases ( [ALT] and/or aspartate aminotransferase [AST]) more than 3 times the (ULN) during the screening period
  5. Presence of any severe concomitant illness(es) that, in the investigator's judgment, would adversely affect the patient's participation in the study
  6. Presence of skin comorbidities that may interfere with study assessments
  7. Females patients who are pregnant or breastfeeding
  8. Female patients who are of and are sexually active, who are unwilling to use adequate methods of
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
78 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Cohort 1 will receive dupilumab dosing regimen 1

    Drug: Dupilumab

  • Experimental
    Cohort 2

    Cohort 2 will receive dupilumab dosing regimen 2

    Drug: Dupilumab

Interventions

  • Also known as: REGN668(SAR231893)

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration

    Peak dupilumab concentration in serum following single dose administration. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.

    Time frame: Day 2, 4, 8, 15, 22, 29, 36, 43, and 50

  2. PK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration

    Mean AUC estimates were calculated using mean concentration data at each time point, using a non-compartmental approach (NCA). Calculated AUClast (computed from time zero to the time of the last positive concentration) are presented. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.

    Time frame: Day 2, 4, 8, 15, 22, 29, 36, 43, and 50

  3. PK of Dupilumab: Trough Dupilumab Concentration in Serum (Ctrough) Before 3rd and 4th Repeated Dose

    Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of study drug.

    Time frame: Pre-dose on Day 71 and Day 85

Secondary outcomes

  1. Percent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD. Analysis was performed on safety analysis set (SAF) that included all subjects who received any study drug. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by last observation carried forward (LOCF).

    Time frame: Baseline to Week 12 (one week after last dose)

  2. Percent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12

    SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis ("Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis". Dermatology (Basel) 186 (1): 23-31. 1993). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 \[absent disease\] to 103 \[severe disease\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.

    Time frame: Baseline to Week 12 (one week after last dose)

  3. Percent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12

    Pruritus NRS scale is an assessment tool that is used to report the intensity of subject's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Subjects were asked the following question: how would a subject rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.

    Time frame: Baseline to Week 12 (one week after last dose)

  4. Percentage of Subjects With Investigator Global Assessment (IGA) Score of "0" or "1" (Clear or Almost Clear) at Week 12

    IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Analysis was performed on SAF. Subjects with rescue treatment usage during the Part B period were specified as non-responders from the time the rescue was used.

    Time frame: Week 12

  5. Percent Reduction From Baseline in Body Surface Area (BSA) at Week 12

    Body surface area affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Analysis was performed on SAF.

    Time frame: Baseline to Week 12

07

Results

Posted Oct 5, 2020

Participant flow

The study was conducted at 25 sites in 6 countries. A total of 88 participants were screened, and of those, 78 participants were randomized with 77 being treated. Ten participants were screen failures as 5 were due to exclusion criteria met \& inclusion criteria not met, 4 participants withdrew consent and 1 participant was lost to follow-up.

Participant flow — Overall Study
MilestoneDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Started20182019
Treated20182019
Completed20182019
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration

Peak dupilumab concentration in serum following single dose administration. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.

Time frame:
Day 2, 4, 8, 15, 22, 29, 36, 43, and 50
Reported as:
Mean · mg/L
Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration
mg/LDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Pharmacokinetics (PK) of Dupilumab: Maximum Plasma Concentration Observed (Cmax) After Single Administration9.91 ± 2.1514.3 ± 5.923.1 ± 8.7132.4 ± 7.04
PrimaryPK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration

Mean AUC estimates were calculated using mean concentration data at each time point, using a non-compartmental approach (NCA). Calculated AUClast (computed from time zero to the time of the last positive concentration) are presented. Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of the study drug.

Time frame:
Day 2, 4, 8, 15, 22, 29, 36, 43, and 50
Reported as:
Mean · Day*mg/L
PK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration
Day*mg/LDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
PK of Dupilumab: Area Under the Plasma Concentration Versus Time Curve (AUClast) After Single Administration104 ± NA160 ± NA362 ± NA330 ± NA
PrimaryPK of Dupilumab: Trough Dupilumab Concentration in Serum (Ctrough) Before 3rd and 4th Repeated Dose

Analysis was performed on PK analysis set that included all treated subjects who received the study medication and had at least 1 quantified (non-missing) result for dupilumab concentration following the first dose of study drug.

Time frame:
Pre-dose on Day 71 and Day 85
Reported as:
Mean · mg/L
PK of Dupilumab: Trough Dupilumab Concentration in Serum (Ctrough) Before 3rd and 4th Repeated Dose
mg/LDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Day 7110.4 ± 7.1617.2 ± 8.4432.8 ± 18.942.1 ± 19.4
Day 8518.5 ± 12.428 ± 12.958.8 ± 24.460.3 ± 36.3
SecondaryPercent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12

The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD. Analysis was performed on safety analysis set (SAF) that included all subjects who received any study drug. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by last observation carried forward (LOCF).

Time frame:
Baseline to Week 12 (one week after last dose)
Reported as:
Mean · percent change
Percent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12
percent changeDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Percent Reduction From Baseline in Eczema Area and Severity Index (EASI) at Week 12-66.4 ± 29.25-76.2 ± 25.48-69.7 ± 24.48-63.4 ± 25.37
SecondaryPercent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12

SCORAD is a clinical tool for assessing the severity of atopic dermatitis developed by the European Task Force on Atopic Dermatitis ("Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis". Dermatology (Basel) 186 (1): 23-31. 1993). Extent and intensity of eczema as well as subjective signs (insomnia, etc.) are assessed and scored. Total score ranges from 0 \[absent disease\] to 103 \[severe disease\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.

Time frame:
Baseline to Week 12 (one week after last dose)
Reported as:
Mean · percent change
Percent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12
percent changeDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Percent Reduction From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 12-47.7 ± 27.27-57.5 ± 23.1-43.4 ± 25.38-46.9 ± 24.31
SecondaryPercent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12

Pruritus NRS scale is an assessment tool that is used to report the intensity of subject's pruritus (itch), both maximum and average intensity, during a 24-hour recall period. Subjects were asked the following question: how would a subject rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]). Analysis was performed on SAF. Data after rescue treatment use during the Part B period were set to missing, then missing values were imputed by LOCF.

Time frame:
Baseline to Week 12 (one week after last dose)
Reported as:
Mean · Percent change
Percent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12
Percent changeDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Percent Reduction From Baseline in Pruritus Numerical Rating Scale (NRS) at Week 12-30.8 ± 68.35-41.6 ± 35.32-37.6 ± 34.42-39.6 ± 40.88
SecondaryPercentage of Subjects With Investigator Global Assessment (IGA) Score of "0" or "1" (Clear or Almost Clear) at Week 12

IGA is an assessment scale used to determine severity of AD and clinical response to treatment on a 5-point scale (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe) based on erythema and papulation/infiltration. Therapeutic response is an IGA score of 0 (clear) or 1 (almost clear). Analysis was performed on SAF. Subjects with rescue treatment usage during the Part B period were specified as non-responders from the time the rescue was used.

Time frame:
Week 12
Reported as:
Number · Percentage of subjects
Percentage of Subjects With Investigator Global Assessment (IGA) Score of "0" or "1" (Clear or Almost Clear) at Week 12
Percentage of subjectsDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Percentage of Subjects With Investigator Global Assessment (IGA) Score of "0" or "1" (Clear or Almost Clear) at Week 121016.73521.1
SecondaryPercent Reduction From Baseline in Body Surface Area (BSA) at Week 12

Body surface area affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]). It was reported as a percentage of all major body sections combined. Analysis was performed on SAF.

Time frame:
Baseline to Week 12
Reported as:
Mean · Percentage of body surface area
Percent Reduction From Baseline in Body Surface Area (BSA) at Week 12
Percentage of body surface areaDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: Children
Percent Reduction From Baseline in Body Surface Area (BSA) at Week 12-61 ± 31.08-70 ± 31.93-60.4 ± 34.04-50 ± 30.8

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the final visit (Week 20) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab 2mg/kg: Adolescents0/20 (0%)1/20 (5%)11/20 (55%)
Dupilumab 2mg/kg: Children0/18 (0%)0/18 (0%)11/18 (61.1%)
Dupilumab 4 mg/kg: Adolescents0/20 (0%)1/20 (5%)16/20 (80%)
Dupilumab 4 mg/kg: Children0/19 (0%)2/19 (10.5%)18/19 (94.7%)
Most frequent serious events
Most frequent serious events
EventDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4 mg/kg: AdolescentsDupilumab 4 mg/kg: Children
Dermatitis atopicSkin and subcutaneous tissue disorders0/200/180/201/19
Arthritis bacterialInfections and infestations0/200/180/201/19
Dermatitis infectedInfections and infestations1/200/181/201/19
PalpitationsCardiac disorders1/200/180/200/19
Staphylococcal skin infectionInfections and infestations0/200/181/200/19
Most frequent other events
Showing 10 of 99
Most frequent other events
EventDupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4 mg/kg: AdolescentsDupilumab 4 mg/kg: Children
NasopharyngitisInfections and infestations2/205/188/2010/19
CoughRespiratory, thoracic and mediastinal disorders0/201/181/207/19
Dermatitis atopicSkin and subcutaneous tissue disorders2/205/183/205/19
Abdominal pain upperGastrointestinal disorders0/200/182/203/19
NauseaGastrointestinal disorders0/200/180/202/19
PyrexiaGeneral disorders2/200/180/202/19
Dermatitis infectedInfections and infestations0/201/182/202/19
RhinitisInfections and infestations0/201/180/202/19
DizzinessNervous system disorders0/200/180/202/19
HeadacheNervous system disorders1/201/181/202/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
Mean14.7 ± 2.018.2 ± 1.6214.3 ± 1.668.2 ± 1.9911.5 ± 3.64
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
Female11911839
Male9991138
Ethnicity
Ethnicity(Participants)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
Hispanic or Latino00011
Not Hispanic or Latino2018201876
Race
Race(Participants)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
White1717151867
Black or African American00112
Asian20305
Other11103
Number of Subjects with Investigator Global Assessment (IGA) score of 3 or 4
Number of Subjects with Investigator Global Assessment (IGA) score of 3 or 4(Participants)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
IGA score of 38111020
IGA score of 4121791957
Eczema Area and Severity Index (EASI) score
Eczema Area and Severity Index (EASI) score(Score on a scale)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
Mean34.8 ± 1732.9 ± 15.5328.6 ± 14.738.8 ± 18.6433.7 ± 16.62
Pruritus Numerical Rating Scale (NRS)
Pruritus Numerical Rating Scale (NRS)(Score on a scale)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
Mean6.1 ± 2.476.4 ± 2.236.9 ± 2.216.7 ± 2.356.5 ± 2.29
Body Surface Area (BSA) Involvement with Atopic Dermatitis (AD)
Body Surface Area (BSA) Involvement with Atopic Dermatitis (AD)(Percentage of body surface area)Dupilumab 2mg/kg: AdolescentsDupilumab 2mg/kg: ChildrenDupilumab 4mg/kg: AdolescentsDupilumab 4mg/kg: ChildrenTotal
Mean52.2 ± 24.7859 ± 22.4945.9 ± 25.3462.3 ± 30.3454.6 ± 26.19

1 further baseline measures are reported on the registry.

08

Study locations

26 sites
  • Markham, Ontario, Canada
  • Peterborough, Ontario, Canada
  • Waterloo, Ontario, Canada
  • Windsor, Ontario, Canada
  • Kutna Hora, Czechia
  • Prague, Czechia
  • Dresden, Germany
  • Frankfurt, Germany
  • Gera, Germany
  • Hamburg, Germany
  • Kiel, Germany
  • Luebeck, Germany
  • Muenster, Germany
  • Munich, Germany
  • Tuebingen, Germany
  • Kaposvar, Hungary
  • Miskolc, Hungary
  • Szeged, Hungary
  • Szolnok, Hungary
  • Katowice, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Warszawa, Poland
  • Wroclaw, Poland
  • Manchester, United Kingdom
  • Sheffield, United Kingdom
09

References and documents

Publications

  • Blauvelt A, Guttman-Yassky E, Paller AS, Simpson EL, Cork MJ, Weisman J, Browning J, Soong W, Sun X, Chen Z, Kosloski MP, Kamal MA, Delevry D, Chuang CC, O'Malley JT, Bansal A. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). Am J Clin Dermatol. 2022 May;23(3):365-383. doi: 10.1007/s40257-022-00683-2. Epub 2022 May 14. PubMed 35567671 ↗
  • Cork MJ, Thaci D, Eichenfield LF, Arkwright PD, Hultsch T, Davis JD, Zhang Y, Zhu X, Chen Z, Li M, Ardeleanu M, Teper A, Akinlade B, Gadkari A, Eckert L, Kamal MA, Ruddy M, Graham NMH, Pirozzi G, Stahl N, DiCioccio AT, Bansal A. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. Br J Dermatol. 2020 Jan;182(1):85-96. doi: 10.1111/bjd.18476. Epub 2019 Oct 8. PubMed 31595499 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Mar 2016, 12 months.

Results were first posted in Oct 2020, 4 years 6 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 12 months is close to that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2015
First posted
Apr 3, 2015
StartActual
Mar 31, 2015
Primary completionActual
Mar 31, 2016
CompletionActual
Mar 31, 2016
Results first posted
Oct 5, 2020
Last update
Nov 27, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 27, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02407756
Collaborators
Sanofi
Responsible party
Sponsor
First posted
Apr 3, 2015
Start date
Mar 31, 2015
Primary completion
Mar 31, 2016
Completion
Mar 31, 2016
Results posted
Oct 5, 2020
Last update
Nov 27, 2020

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion